Manufacturer Recalls Natpara

The manufacturer of Natpara has recalled the drug used to treat adults with chronic hypoparathyroidism.

The Takeda pharmaceutical company issued the recall to remove all Natpara products. This includes all injection dosages: 25, 50, 75 and 100 mcg.

What You Need to Know
Even though this recall impacts a small segment of our provider community and member population for our commercial and Medicare lines of business, we are sharing the information with all providers.

The recall is related to a potential issue with rubber particulates originating from the rubber septum of the Natpara cartridge. During the 14-day treatment period, the septum is punctured by a needle each day. When the septum is repeatedly punctured, it is possible that small rubber fragments may detach into the cartridge.

Next Steps
Prime Therapeutics, our pharmacy benefit manager, is notifying impacted Florida Blue providers reminding them not to discontinue Natpara abruptly as it can result in hypocalcemia. Physicians should monitor for signs and symptoms of hypocalcemia and serum calcium levels.

We’re advising Florida Blue members who take Natpara to contact you for medical recommendations.

This is not intended as a complete description of benefits and risks for the use of Natpara. For additional information, please call Takeda at 800-828-2088 or visit natpara.com.